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The sarcoma ﬁeld is at a crossroads. There have been in-
credible advances in the identiﬁcation and characterization
of key genetic events associated with sarcoma development.
For example, many chromosomal translocation breakpoints
have been cloned, and the fusion proteins associated
with those breakpoints have been subjected to rigorous
molecular analysis. Similarly, there has been an explosion
of molecularly targeted agents available for the treatment
of patients with cancer. In cases where these targeted agents
inhibit a key abnormality in sarcoma, such as activated
KIT in gastrointestinal stromal tumor, they have been quite
successful. Unfortunately, examples of such success are still
limited. Many investigators in the ﬁeld have hoped that
deeper understanding of the molecular basis of sarcoma may
lead to new therapeutic opportunities for this varied set of
diseases.
It is with this spirit that the current special issue is pre-
sented. Twenty-three papers are included, which cover a
vast range in the ﬁeld and include a mix of both original
research and timely reviews. Through the process of pre-
senting a broad array of molecular topics related to sarcoma
development, it is our hope that investigators and other
interested parties will recognize both common threads and
unique issues across many diﬀerent subtypes of sarcoma and
that such recognition will stimulate new research directions
that will lead to new cures for patients suﬀering from these
diseases.
In the ﬁrst paper of the special issue, “Epigenetic regula-
tion of apoptosis and cell cycle in osteosarcoma,” Kleinerman
and K. Rao-Bindal critically discuss frequency and prognos-
tic impact of epigenetic inactivation of p16/p14ARF, HIC1,
and RASSF1A in this disease, as well as the possible role
of histone H3 lysine 27 monomethylation in osteosarcoma
apoptosis. This provides unique insights into the role of epi-
genetics as a molecular basis for osteosarcoma development.
High-dose methotrexate is a mainstay of modern
osteosarcoma therapy. While osteosarcomas respond well to
high-dose methotrexate, they do not respond well to con-
ventional doses of the drug. The second article, “Impairment
of methotrexate transport is common in osteosarcoma tumor
samples” by R. Sowers et al., demonstrates that methotrexate
transport is impaired in high-grade osteosarcoma. This
suggeststhathighdosesoftheagentarerequiredtoovercome
this transport impairment, and implies that antifolate agents
that are not dependent on the common transport pathway
m i g h tb em o r ee ﬀective for this disease.
In the third article, “The molecular pathogenesis of
osteosarcoma: a review,” M. L. Broadhead et al., provide an
extensive and timely discussion of the current knowledge on
the etiology of the disease and more frontline translational
studies aiming at targeted osteosarcoma therapy.
In the next review, “Osteosarcomagenesis: modeling cancer
initiation in the mouse, ”K .B .J o n e st r a c e st h eh i s t o r i c a l
pathways for developingnonclinical models of osteosarcoma
to the more contemporary genetically engineered mouse
models and how they recapitulate the human disease. The
workpresentsearlyapproachestocreatingnon-clinicalmod-
elsthatinvolvedrandommutagenesis,boneseekingradionu-
clides, external beam radiation, viral insertional mutagenesis
and how these models informed human osteosarcoma. The
review also details current approaches using gene targeting
to engineer mouse models, and their value and limitations.
Although osteosarcoma displays features of poorly dif-
ferentiated osteoprogenitors, the exact histogenesis is still
unknown. In the ﬁfth article, “Defective osteogenic diﬀeren-
t i a t i o ni nt h ed e v e l o p m e n to fo s t e o s a r c o m a ,” W. R. Wagner2 Sarcoma
et al., assess the problem of osteosarcoma pathogenesis
from a developmental angle. In their review they discuss
osteosarcoma as a disease of impaired diﬀerentiation, and
summarize the rationale and ﬁrst data on the use of
diﬀerentiation inducing agents as a potential therapeutic
strategy in this disease.
Understanding normal development and how these
processes go awry in cancer has important implications
for understanding tumorigenesis, and for considering new
therapeutic approaches. With this in mind, the sixth article,
“The role of RUNX2 in osteosarcoma oncogenesis,” by J. W.
Martin et al., reviews the RUNX2 transcription factor and
its potential role in osteosarcoma. RUNX2is a DNA-binding
transcription factor that is involved in normal bone devel-
opment. RUNX2 is often overexpressed in osteosarcoma,
and so its normal functions may also be important for the
development of the tumor.
Continuing onwith theosteosarcoma theme,theseventh
article, “Using epidemiology and genomics to understand
osteosarcoma etiology,” by S. A. Savage and L. Mirabello, pro-
vides a comprehensive review of the epidemiology of osteo-
sarcoma, and also reviews the known genomic mutations
and variants that are associated with osteosarcoma de-
velopment. This review is particularly timely given expand-
inginterest inlarge-scale studiesofpediatric cancerepidemi-
ology and genomics.
Transcription factor fusions involving the EWS gene
or one of its relatives FUS or TAF15 in sarcomas or
rare leukemias are considered dominant oncogenes. How-
ever, since EWS family proteins are ubiquitously expressed
housekeeping proteins, allelic rearrangements may result in
haploinsuﬃciency or even a dominant negative eﬀect on the
remaining expressed allele.Nuclearlocalizationis considered
an essential prerequisite for the normal function of EWS
family proteins. In the eighth paper, “Tyrosine phosphory-
lation in the C-terminal nuclear localization and retention
signal (C-NLS) of the EWS protein,” R. P. Leemann-Zakaryan
et al., describe the role of C-terminal phosphorylation in
physiological control of EWS nuclear localization, which is
lost upon rearrangement with a transcription factor moiety
in sarcoma.
In the ninth article, “D r .J e k y l la n dM r .H y d e ,t h et w o
facesoftheFUS/EWS/TAF15proteinfamily,” H. Kovar reviews
the interesting dual personality of the FUS/EWS/TAF15
proteins. On the one hand, these proteins have a variety of
wild-type functions that are important to normal cellular
behavior that are slowly being worked out. On the other
hand, they are evil fusion partners in oncogenesis. It seems
likely that the oncogenic functions (both transcriptional and
nontranscriptional) are related to the normal functions of
these proteins.
In the next article, “Copy number alterations (CNAs)
and methylation in Ewing’s sarcoma,” M. S. Jahromi et al.,
provide a comprehensive literature review of available data
reporting copy number alterations (CNA’s), alterations in
mitochondrial DNA, and gene silencing by methylation for
Ewing’s sarcoma. The potential implication of trisomy 8 and
12, gains on chromosome 2q, and deletion or methylation
silencing of the CDKN2A (p16-INK4a) locus, or genes
involved in the extrinsic death pathway for patient outcome
are reviewed. This work provides an overview of intriguing
data, limited by sample size, that points to the pathogenesis
of Ewing’s sarcoma, and the potential to impact treatment
outcome through large-scale studies that are now possible
using archival tissue.
In the eleventh article, “Targeting angiogenesis in child-
hoodsarcomas,”H.K.BidandP.J.Houghtonprovideatimely
and comprehensive evaluation of the literature regarding
angiogenesis and vasculogenesis in sarcomas (particularly,
pediatric sarcomas). In addition to reviewing the data
regarding the biologic basis for these processes, the authors
also review a series of therapeutic strategies based on
inhibiting angiogenesis and vasculogenesis, in sarcoma.
In the twelfth article, “Immune-based therapies for sar-
coma,” S. M. Pollack et al., point out that there are great
unmet needs in the systemic therapy of sarcomas and
that nonchemotherapeutic strategies might be exploited
for this role. The authors provide an important review
of immunotherapy in sarcoma and discuss a variety of
therapeutic trials and concepts in the ﬁeld, including non-
speciﬁc immunomodulation and targeted immunotherapy
approaches. This review highlights the opportunities, and
remaining challenges, that exist in allowing immunotherapy
to become a part of the armamentarium to treat sarcomas in
the future.
IGF signaling is an important component of the machin-
ery driving cellular growth in embryonal tissues and in
manytumors.Itwasthereforeexpectedthatanti-IGFtherapy
should be a promising therapeutic option in the treatment
of cancer, particularly of sarcomas in which IGF signaling is
constitutively activated. In the thirteenth article, “Targeting
the insulin-like growth factor pathway in rhabdomyosarcomas:
rationale and future perspectives,” A. S. Martins et al.,
discuss the role of IGF signaling in rhabdomyosarcoma and
summarize ﬁrst clinical experience and so far unexplored
options of combination chemotherapy.
The articlebyL. E.S.Croseand C.M.Linardic, “Receptor
tyrosine kinases as therapeutic targets in rhabdomyosarcoma,”
reviews the current knowledge regarding expression of
tyrosine kinase receptors in rhabdomyosarcoma. The review
presents up-to-date information on expression in clinical
samples of speciﬁc receptor kinases including members of
the epidermal, hepatocyte, ﬁbroblast, platelet and insulin-
like growth factors and their potential role in tumorigenesis
as shown in genetically engineered models. The review
details current ongoing clinical studies of agents that target
these receptors and discusses the future development of
these agents in the context of contemporary therapeutic
approaches to rhabdomyosarcoma.
Among the various cellular stresses which tumor cells
havetoevadeinordertosurviveandproliferateisamarkedly
increased production of reactive oxygen species (ROS). In
the ﬁfteenth paper, “The role of mirk kinase in sarcomas”, E.
Friedman discusses how the activity of the serine/threonine
kinase Mirk/dyrkB may prevent apoptosis of osteosarcoma
and rhabdomyosarcoma cells by increasing the expression
of antioxidant scavenger proteins. Dr. Friedman reviews the
literature on the role of Mirk as a potential prognosticSarcoma 3
biomarker in osteosarcoma, and on the therapeutic promise
of Mirk inhibition in combination of chemotherapy with
conventional anticancer drugs.
The sixteenth paper, “miRNA proﬁling: how to bypass the
current diﬃculties in the diagnosis and treatment of sarcomas,”
A. Gougelet et al., demonstrate that real-time quantitative
PCR approaches focused on microRNA (miRNA) signa-
tures provide a new prognostic and diagnostic approach
in two important sarcoma types: osteosarcoma and rhab-
domyosarcoma. In the case of osteosarcoma, miRNAproﬁles
changed in uniqueandpredictive waysfollowing exposure to
chemotherapeutic agents, which suggests that such proﬁles
might be used in a prognostic fashion. In the case of rhab-
domyosarcoma, miRNA proﬁles were diagnostic of each of
the subtypes of rhabdomyosarcoma. Thus, miRNA proﬁling
may have important use in the diagnostic and prognostic
analysis of at least some types of sarcoma.
The next paper, “Delineation of chondroid lipoma; an
immunohistochemicalandmolecularbiologicalanalysis,” by de
Vreeze et al., presents a study from the Dutch Pathology Reg-
istry of chondroid lipomas, extremely rare benign tumors.
Chondroid lipoma may exhibit histologic features resem-
bling myoepithelioma, myxoid liposarcoma, extraskeletal
myxoid chondrosarcoma, hibernoma, and other lipomatous
or chondroid neoplasms, resulting in diﬃculties in accurate
diagnosis with an appropriate treatment. The aim of this
study was to delineate chondroid lipoma from several mor-
phologic mimics by the means of immunohistochemistry.
Althoughthese tumors show high expression of CCND1,the
authors rule out the CCND1 and FUS genes as candidates
involved in the t(11;16)(q13;p13) previously reported as
a recurrent translocation in this rare benign lipomatous
tumor.
While chondrocytes are mesenchymal in nature, chon-
drosarcomas exhibit features of epithelial cells as well. The
eighteenth article, “Human chondrosarcoma cells acquire
an epithelial-like gene expression pattern via an epigenetic
switch: evidence for mesenchymal-epithelial transition during
sarcomagenesis,” by M. P. Fitzgerald et al., provides evidence
for epigenetic activation of a set of epithelial markers in
chondrosarcomas, and downregulation of snail, as compared
to chondrocytes. These data suggest that chondrosarcomas
undergo a mesenchymal to epithelial transition via an epige-
netic pathway.
In the next article, “Spinal chondrosarcoma: a review,” P.
Katonis and colleagues present a comprehensive review of
spinal chondrosarcoma, a rare variant comprising 10 percent
of chondrosarcoma patients. The review covers histologic
classiﬁcation and molecular characteristics associated with
disease progression, subtype classiﬁcation, and risk factors.
Radiologicfeaturesassociatedwithdiagnosisandstagingand
current approaches to therapy and prognosis are discussed.
Dermatoﬁbrosarcoma protuberans (DFSP) is a rare
cutaneous-origin sarcoma associated with constitutive acti-
vationofthereceptortyrosinekinase(RTK)PDGFRbychro-
mosomal rearrangement with the collagen gene COL1A1. In
the twentieth paper, “Advances in molecular characterization
and targeted therapy in dermatoﬁbrosarcoma protuberans
(DFSP),” P. Rutkowski et al., discuss their clinical results
obtained with the broad spectrum RTK inhibitor Imatinib
in the treatment of inoperable and/or metastatic and/or
recurrent cases of DFSP.
Clinically,distinguishingbenignuterineleiomyomafrom
malignant uterine leiomyosarcoma (LMS) remains a chal-
lenge. The next article, “Molecular approach to uterine leio-
myosarcoma: LMP2-deﬁcient mice as an animal model of
spontaneous uterine leiomyosarcoma,” by T. Hayashi et al.,
reviews the molecular pathogenesis of LMS, with speciﬁc
reference to the role of LMP2, a gene encoding a component
of the immunoproteasome, in development of uterine
leiomyosarcoma. They report that uterine LMS occurred in
female LMP2-deﬁcient mice at age of 6 months and the
incidence at 14 months of age was about 40%. They identify
LMP2, a single IFN-γ-responsive gene product,as obligatory
for tumor surveillance and demonstrate a tissue-speciﬁc role
for LMP2 in protection from spontaneous neoplasms of
the uterus. The potential for use of LMP2 expression as a
diagnostic marker to distinguish leiomyoma from LMS is
proposed.
Recently, great advances have been made in understand-
ing the molecular basis of diﬀerent types of liposarcoma. In
the twenty-second article, “Liposarcoma: molecular genetics
and therapeutics,” S. Young et al., review the molecular basis
for liposarcoma, with a focus on recent molecular genetic
datafromtechniquessuchasﬂuorescentinsituhybridization
(FISH) and comparative genomic hybridization (CGH). In
somecases,thesemolecularchanges(suchasampliﬁcationof
MDM2 and CDK4) suggest rational therapeutic approaches
for these diseases, which are also reviewed.
Sarcomas tend to metastasize to lungs and bones, and
preventionofmetastasis isconsideredtheholygrailofcancer
treatment. In the ﬁnal article of the issue, “The role of
chemokine receptor CXCR4 in the biologic behavior of human
soft tissue sarcoma”, R. H. Kim et al., review the growing body
of evidence that chemokine receptors, speciﬁcally CXCR4,
play an important role in homing of sarcoma cells to lung
and bones. Data are discussed that imply CXCR4 inhibitors
as promising add-ons to classical chemotherapy to prevent
deadly metastases in sarcoma patients.
Clearly there are great challenges, but also great oppor-
tunities, to link the molecular basis of sarcoma (and all
of its relevant associated phenotypes) to new diagnostic,
prognostic, and therapeutic approaches for this complex
group of malignancies. We hope that the articles in this
special issue provide a strong stimulus for such a linkage
and will help to spur ongoing advances that will ultimately
transform the care of patients with sarcoma.
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